Methylphenidate

Methylphenidate (MPH) is an amphetamine-like prescription stimulant commonly used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children and adults. It is also one of the primary drugs used to treat symptoms of traumatic brain injury and the daytime drowsiness symptoms of narcolepsy and chronic fatigue syndrome. Brand names of drugs that contain methylphenidate include Ritalin® (Ritalina®, Rilatine®), Concerta® (a timed-release capsule), Metadate®, Methylin® and Rubifen®. Focalin® is a preparation containing only dextro-methylphenidate, rather than the usual racemic dextro- and laevo-methylphenidate mixture of other formulations.

History

Methylphenidate was patented in 1954 by the Ciba pharmaceutical company (one of the predecessors of Novartis) and was initially prescribed as a treatment for depression, chronic fatigue, and narcolepsy, among other ailments. Beginning in the 1960s, it was used to treat children with ADHD, known at the time as hyperactivity or minimal brain dysfunction (MBD). Today methylphenidate is the medication most commonly prescribed to treat ADHD around the world. According to most estimates, more than 75 percent of methylphenidate prescriptions are written for children, with boys being about four times as likely to take methylphenidate as girls. Production and prescription of methylphenidate rose significantly in the 1990s, especially in the United States, as the ADHD diagnosis came to be better understood and more generally accepted within the medical and mental health communities. Methylphenidate has been used illegally by students for whom the drug has not been prescribed, to assist with coursework and examinations.

While ADHD medication is directed for children, it has not been studied for children under the age of 6. It is also important to not that while ADHD is a condition that includes hyperactivity, problems holding still, and following directions, this is also typical of a child under the age of 6. This causes difficulty in diagnosing children under this age and should probably not be studied.

Most brand-name Ritalin is produced in the United States, although methylphenidate is also produced in Mexico and Argentina by respective contract pharmaceutical manufacturers and is most commonly marketed under the brand name "Ritalin" for Novartis. In the United States, various generic forms of methylphenidate are also produced by several pharmaceutical companies (such as Methylin, etc.), and Ritalin is also sold in the United Kingdom, Germany, and other European countries (although in much lower volumes than the United States). These generic versions of methylphenidate tend to outsell brand-name "Ritalin" four-to-one. In Belgium the product is sold under the name "Rilatine" for Novartis.

Another medicine is Concerta, a once-daily extended release form of methylphenidate, which was approved in April 2000. Studies have demonstrated that long-acting methylphenidate preparations such as Concerta are just as effective, if not more effective, than IR (instant release) formulas. Time-release medications are also harder to misuse.

In April 2006, the FDA approved a transdermal patch for the treatment of ADHD, called Daytrana. The once-daily patch administers methylphenidate in doses of 10, 15, 20, or 30mg. However, the patch must be applied several hours before the effect is desired, and the drug's effect remains for several hours after removal, making it necessary to remove the patch in the mid-to-late afternoon or else insomnia may result.

Effects

Methylphenidate is a central nervous system (CNS) stimulant. It is claimed to have a "calming" effect on many children who have ADHD [citations needed], reducing impulsive behaviour and the tendency to "act out", and helps them concentrate on schoolwork and other tasks. Adults who have ADHD often find that MPH increases their ability to focus on tasks and organise their lives.

Methylphenidate has been found to have a lower incidence of side-effects compared to dextroamphetamine, a less commonly prescribed medication. When prescribed at the correct dosage, methylphenidate is usually well-tolerated by patients.

The means by which methylphenidate helps people with ADHD are not well understood. Some researchers have theorized that ADHD is caused by a dopamine imbalance in the brains of those affected. MPH is a dopamine reuptake inhibitor, which means that it increases the level of the dopamine neurotransmitter in the brain by partially blocking the transporters that remove it from the synapses.

In the United States, methylphenidate is classified as a Schedule II controlled substance, the designation used for substances that have a recognized medical value but which have a high potential for abuse because of their addictive potential. Internationally, methylphenidate is a Schedule II drug under the Convention on Psychotropic Substances. Some people abuse MPH by crushing the tablets and snorting them, the "high" resulting from the increased rate of dopamine transporter blockade due to quicker absorption into the bloodstream. In this manner, the effect of Ritalin is similar to that of cocaine or amphetamine and such abuse can lead to addiction. When taken orally in prescribed doses, MPH has a low addiction liability and rarely produces a "high".

Side effects

Common reported side effects are: difficulty sleeping (which can lead in turn to other problems); loss of appetite (thus its use as an appetite suppressant); irritability; nervousness; stomach aches; headaches; dry mouth; blurry vision; nausea; dizziness; drowsiness; motor tics or tremors. Up to 5% of children experience disturbing hallucinations often involving worms, snakes, or insects (New Scientist, 31 March 2006).

Less common side effects are: hypersensitivity; anorexia; palpitations; blood pressure and pulse changes; cardiac arrhythmia; anaemia; scalp hair loss; toxic psychosis.

There have also been reports of: abnormal liver function; cerebral arteritis; leukopaenia; death. There have been at least 19 cases of sudden death in children taking methylphenidate, leading to calls by the Drug Safety and Risk Management Advisory Committee to the FDA to require the most serious type of health warning on the label, but this advice was rejected (New Scientist 18 Feb. 2006).

Medline lists a number of side-effects of unquantified frequency.

Formulations

Most products containing methylphenidate contain a racemic mixture of dextro-methylphenidate and levo-methylphenidate, although it is only dextro-methylphenidate, the active enantiomer, which is considered to provide the pharmacologically useful effects of mental focus. However, with the introduction of Focalin, pure dextro-methylphenidate is available. Described as a fast-acting form of the drug, it is absorbed more quickly by the body, with a shorter time to peak concentration (and excretion) than with the racemic compound.

The pharmacological profiles and relative usefulness of dextro- and levo-methylphenidate is analogous to what is found in amphetamine, where dextro-amphetamine is considered to have a more beneficial effect than levo-amphetamine.

Delivery

Ritalin: 5 mg, 10 mg and 20 mg tablets;

Ritalin SR: 20 mg tablets;

Ritalin LA: 20 mg, 30 mg and 40 mg capsules;

Methylin: 5 mg, 10 mg, and 20 mg tablets;

Methylin ER: 10 mg and 20 mg tablets;

Metadate ER: 10 mg and 20 mg tablets;

Metadate CD: 10 mg, 20 mg and 30 mg capsules;

Concerta: 18 mg, 27 mg, 36 mg and 54 mg tablets;

Equasym: 5 mg, 10 mg tablets;

Rubifen: 5 mg, 10 mg and 20 mg tablets;

Daytrana: 10 mg, 15 mg, 20 mg, 30 mg and 40 mg patches

Criticism

Similarity to Cocaine

Like cocaine, methylphenidate is a powerful stimulant that increases alertness and productivity. Methylphenidate and cocaine have similar chemical structures. Their effects, too, are similar; both increase the brain-levels of dopamine -- a joy-inducing neurotransmitter -- by blocking the ability of neurons to reabsorb dopamine. When taken as prescribed, however, Methylphenidate is absorbed into the body at a much slower rate than cocaine. In this way, methylphenidate is like low-dosage, slow-acting cocaine. The similarities between methylphenidate and cocaine have prompted concern that the unknown dangers of methylphenidate could be similar to the known dangers of cocaine.

Overprescription

The incidence of ADHD is believed to be between three and five percent of the population, while the number of children in America taking Ritalin is estimated at one to two percent. In a small study of four American communities, the incidence of ADHD varied from 1.6% to 9.4%. The study also found that 12.5% of the children meeting the DSM-III-RADHD criteria for ADHD had been treated with stimulants during the past year.

Addiction

Some have argued that prescription of stimulant medications sets children up for future addictions. However, recent research suggests that boys with ADHD who are treated with stimulants like MPH are actually less likely to abuse drugs including alcohol later in life.

Long-term effects

Ritalin has been used on a long-term basis since the mid-20th century, yet clinical studies of the long-term use effects have not been undertaken. A great deal of controversy has been generated by non-expert groups, many of them basing 'research' on the negative effects of ritalin on children. Many of these reports have been forwarded by Scientology-related groups.

In a 2005 study, no "clinically significant" effects on growth, vital signs, tics, or laboratory tests (including urinalysis, hematology/complete blood counts, electrolytes, and liver function tests) were observed after 2 years of treatment.

Still, some theoretical studies raise theoretical questions. For example, Adriani et al (2005) found plastic changes in reward related behaviour in rats after they were in a drug-free state. Whether or not this would have any effect on human cognition is unknown.

Effects on stature

Researchers have also looked into the role of methylphenidate in affecting stature, with some studies finding slight decreases in height acceleration. Other studies indicate height may normalize by adolescence.

Risk of death

As mentioned above, methylphenidate has been implicated in cases of sudden death by heart failure. The FDA decided against requiring warning labels, even though its advisory committee voted in favor of this.

Potential Carcinogen

In February 2005, a team of researchers from The University of Texas M.D. Anderson Cancer Center led by R.A. El-Zein announced that a small scale study of 12 children indicated that methylphenidate may be carcinogenic. In the study, 12 children were given standard therapeutic doses of methylphenidate. At the conclusion of the 3 month study, all 12 children displayed significant, treatment induced chromosomal aberrations. The researchers indicated that while their study was relatively small, they indicated the results should be reproduced one more time in a bigger population for a definitive conclusion about the genotoxicity of methylphenidate to be drawn. The link between chromosomal aberrations and cancer risk has been established.

The results are controversial, however, since there have been conflicting results regarding the mutagenicity of methylphenidate.

A 2003 study tested the effects of d-methylphenidate (Focalin), l-methylphenidate, and d,l-methylphenidate (Ritalin) on mice to search for any carcinogenic effects. The researchers found that all three compounds were non-genotoxic and non-clastogenic; d-MPH, d,l-MPH, and l-MPH did not cause mutations or chromosome aberrations. They concluded that none of the compounds present a carcinogenic risk to humans.

In 2005, the U.S. Food and Drug Administration issued a series of public health advisories warning that Ritalin and its sister drugs may cause visual hallucinations, suicidal thoughts, psychotic behaviour, as well as agression or violent behaviour.

Illicit use

Both the United States Drug Enforcement Administration (DEA) and the United Nations International Narcotics Control Board have expressed concern about the ease with which legally prescribed MPH is diverted to the illicit market.

According to the DEA, "The increased use of this substance [MPH] for the treatment of ADHD has paralleled an increase in its abuse among adolescents and young adults who crush these tablets and snort the powder to get high. Youngsters have little difficulty obtaining methylphenidate from classmates or friends who have been prescribed it."

American psychiatry's infatuation with the brain coincides with a drug industry more than happy to contribute funds for research that only counts symptoms and pills. If only family counseling or special education rewarded stockholders the same way Ritalin or Prozac [fluoxetine hydrochloride] does. (Diller, West J Med, Dec. 2000)

Street names for ritalin include: diet coke, kiddie cocaine, kiddie coke, vitamin R, R-ball, poor man's cocaine, rids, skittles, and smarties.

© Medic8 ® All Rights Reserved.